Supplementary Material for: Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor (ICI)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)

Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the "Delphi" consensus formation method, and finally revised and completed the "Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 edition. This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.

以免疫检查点抑制剂（Immune Checkpoint Inhibitor, ICI）为基础的肝细胞癌（hepatocellular carcinoma, HCC）联合治疗方案，在临床研究与实践中已取得显著疗效，成为不可切除肝细胞癌治疗的主流方案。为帮助临床医师更合理、有效且安全地应用联合免疫治疗药物及方案，编委会组织该领域多学科专家开展研讨，采用德尔菲（Delphi）共识形成方法，并在2021版基础上修订完善了《中国肝细胞癌免疫检查点抑制剂（ICIs）联合治疗多学科专家共识（2023版）》。本共识重点围绕免疫检查点抑制剂联合治疗的临床实践原则与方法，旨在基于最新研究进展与专家经验总结临床应用推荐意见，为临床医师提供应用指导。